Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.

Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE.

Immunol Lett. 2012 Mar 30;143(1):34-43. doi: 10.1016/j.imlet.2012.01.008. Epub 2012 Jan 25.

PMID:
22305932
2.

An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.

Wigginton SJ, Furtado PB, Armour KL, Clark MR, Robins A, Emara M, Ghaemmaghami AM, Sewell HF, Shakib F.

Clin Exp Allergy. 2008 Feb;38(2):313-9. Epub 2007 Dec 7.

PMID:
18070161
3.

Improved FcγRIIb targeting functionally translates into enhanced inhibition of basophil activation.

Buschor P, Eggel A, Zellweger F, Stadler BM, Vogel M.

Int Arch Allergy Immunol. 2014;163(3):206-14. doi: 10.1159/000358487. Epub 2014 Feb 14.

PMID:
24557487
4.

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.

Chu SY, Horton HM, Pong E, Leung IW, Chen H, Nguyen DH, Bautista C, Muchhal US, Bernett MJ, Moore GL, Szymkowski DE, Desjarlais JR.

J Allergy Clin Immunol. 2012 Apr;129(4):1102-15. doi: 10.1016/j.jaci.2011.11.029. Epub 2012 Jan 16.

PMID:
22257644
5.

Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein.

Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A.

J Allergy Clin Immunol. 2004 Aug;114(2):321-7.

PMID:
15316510
6.

Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions.

Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K, Panakos JA, Chourmouzis E, Liu FT, Lau CY.

J Exp Med. 1996 Jan 1;183(1):49-56.

7.

Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein.

Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M.

Allergy. 2011 Jul;66(7):961-8. doi: 10.1111/j.1398-9995.2011.02546.x. Epub 2011 Jan 28.

8.

Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes.

Kepley CL, Taghavi S, Mackay G, Zhu D, Morel PA, Zhang K, Ryan JJ, Satin LS, Zhang M, Pandolfi PP, Saxon A.

J Biol Chem. 2004 Aug 20;279(34):35139-49. Epub 2004 May 19.

9.
10.

Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.

Daëron M, Malbec O, Latour S, Arock M, Fridman WH.

J Clin Invest. 1995 Feb;95(2):577-85.

11.

Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.

Saxon A, Zhu D, Zhang K, Chan LA, Kepley CL.

Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):223-31; discussion 231-3.

PMID:
17393744
12.

FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.

Safaralizadeh R, Soheili ZS, Deezagi A, Pourpak Z, Samiei S, Moin M.

Iran J Allergy Asthma Immunol. 2009 Dec;8(4):177-83. doi: 08.04/ijaai.177183.

13.

Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG.

Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T.

J Exp Med. 1999 May 17;189(10):1573-9.

15.

A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.

Mertsching E, Bafetti L, Hess H, Perper S, Giza K, Allen LC, Negrou E, Hathaway K, Hopp J, Chung J, Perret D, Shields M, Saxon A, Kehry MR.

J Allergy Clin Immunol. 2008 Feb;121(2):441-447.e5. Epub 2007 Oct 18.

PMID:
17949802
16.
17.

Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils.

Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, Oliver JM.

J Allergy Clin Immunol. 2000 Aug;106(2):337-48.

PMID:
10932079
19.

Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases.

Saxon A, Zhu D, Zhang K, Allen LC, Kepley CL.

Curr Opin Allergy Clin Immunol. 2004 Dec;4(6):563-8. Review.

PMID:
15640700
20.

Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.

Belostotsky R, Lorberboum-Galski H.

Clin Immunol. 2004 Jan;110(1):89-99.

PMID:
14962800

Supplemental Content

Support Center